Insiders

29/04 Sanofi Announces Board and Committee Changes CI
07/04 Sanofi: Treatment for re-rating isn’t easy Alphavalue
05/03 Sanofi Announces Resignation of Patrick Kron as Independent Director and Chairman of the Nomination, Governance and Csr Committee CI
24/02 Alveus Therapeutics, Inc. announced that it has received $197 million in funding from a group of investors CI
17/02 Sanofi Announces Executive Changes CI
17/02 Sanofi appoints Manuela Buxo as head of specialty care RE
13/02 PRESS DIGEST-Financial Times - February 13 RE
12/02 Jefferies Identifies the Key Challenge for Sanofi's New CEO Zonebourse
12/02 Sanofi Shares Fall After CEO Change DJ
12/02 Sanofi Announces Chief Executive Officer Changes CI
12/02 The Pill Is Hard to Swallow for Investors Zonebourse
12/02 Sanofi Names Belen Garijo as Chief Executive MT
12/02 Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant RE
12/02 Belén Garijo to become chief executive officer of Sanofi RE
12/02 Sanofi appoints Belén Garijo as new CEO after deciding not to renew current CEO Hudson's mandate RE
12/02 Sanofi Names Merck KGaA's Belen Garijo to Replace Paul Hudson as CEO -- Update DJ
12/02 Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant RE
12/02 Sanofi Names Belen Garijo to Replace Paul Hudson as CEO DJ
12/02 Sanofi Appoints Former Merck KGaA Executive as New CEO MT
12/02 Belén Garijo to Replace Paul Hudson as Head of Sanofi Zonebourse
08/01 Alveus Therapeutics ApS announced that it has received $159.8 million in funding from New Rhein Healthcare Investors, LLC, Andera Partners, Omega Fund Management, LLC, Kurma Partners SA, Avego BioScience Capital, Sanofi and other investors CI
08/01 Alveus Therapeutics, Inc. amended terms of the transaction CI
08/25/08 Biovaxys appoints former Sanofi Vaccines executive to board of directors RE
01/25/01 Sanofi: Pipeline disappointments may push out the CEO Alphavalue
30/25/30 Sanofi Appoints Clotilde Delbos as Chairwoman of the Compensation Committee CI
No results match your criteria
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!